Santhera Pharmaceuticals Holding AG/€SANN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG is a Swiss pharmaceutical company focused on the development and commercialization of innovative treatments for rare and debilitating diseases. The company's key areas of expertise include neuromuscular and pulmonary disorders. Santhera's product pipeline features several investigational drugs targeting conditions such as Duchenne muscular dystrophy and cystic fibrosis. Headquartered in Pratteln, Switzerland, the company leverages its scientific expertise and industry partnerships to advance its therapeutic offerings. Santhera's strategic focus on niche markets allows it to address unmet medical needs, providing potential opportunities for growth within specialized segments of the healthcare industry.
- Ticker
- €SANN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 94
- Headquarters
- Pratteln, Switzerland
- Website
- www.santhera.com
SANN Metrics
BasicAdvanced
€246M
-
-€2.51
-0.39
-
Price and volume
Market cap
€246M
Beta
-0.39
52-week high
€19.40
52-week low
€12.30
Average daily volume
71K
Financial strength
Current ratio
1.729
Quick ratio
1.102
Long term debt to equity
-4.9
Total debt to equity
-6.686
Interest coverage (TTM)
-0.50%
Profitability
EBITDA (TTM)
-3.941
Gross margin (TTM)
40.98%
Net profit margin (TTM)
-31.46%
Operating margin (TTM)
-8.60%
Effective tax rate (TTM)
-0.44%
Revenue per employee (TTM)
€1,170,160
Management effectiveness
Return on assets (TTM)
-3.93%
Return on equity (TTM)
731.00%
Valuation
Price to revenue (TTM)
2.017
Price to book
-36.07
Price to tangible book (TTM)
-3.29
Price to free cash flow (TTM)
319.399
Free cash flow yield (TTM)
0.31%
Free cash flow per share (TTM)
0.05
Growth
Revenue change (TTM)
107.08%
Earnings per share change (TTM)
-57.24%
3-year revenue growth (CAGR)
169.91%
10-year revenue growth (CAGR)
25.98%
3-year earnings per share growth (CAGR)
-31.87%
10-year earnings per share growth (CAGR)
-13.14%
What the Analysts think about SANN
Analyst ratings (Buy, Hold, Sell) for Santhera Pharmaceuticals Holding AG stock.
Analyst projections of the future price of Santhera Pharmaceuticals Holding AG stock.
SANN Financial Performance
Revenues and expenses
SANN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.